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Abstract
In Iran, the prevalence of hepatitis C virus (HCV) 
infection is relatively low according to the population-
based epidemiologica l  studies.  However,  the 
epidemiology of HCV is changing and the rate of HCV 
infection is increasing due to the growth in the number 
of injecting drug users in the society. In addition, a shift 
has occurred in the distribution pattern of HCV genotypes 
among HCV-infected patients in Iran. Genotype 1a is the 
most prevalent genotype in Iran, but in recent years, 
an increase in the frequency of 3a and a decrease in 
1a and 1b have been reported. These variations in the 
epidemiology of HCV reflect differences in the routes of 
transmission, status of public health, lifestyles, and risk 
factors in different groups and geographic regions of Iran. 
Health policy makers should consider these differences to 
establish better strategies for control and prevention of 
HCV infection. Therefore, this review was conducted to 
present a clear view regarding the current epidemiology 
of HCV infection in Iran.
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Core tip: The distribution patterns of hepatitis C virus 
(HCV) infection are related to different status of public 
health and the presence of risk factors in the society. In 
Iran, the predominance of risk factors for transmission 
of HCV has changed from blood transfusion to 
intravenous drug use; and due to the growth in the 
number of injecting drug users, the prevalence of 
HCV infection is rising in the country. Even the recent 
changes in the distribution pattern of HCV genotypes 
confirm this issue. Overall, the epidemiology of HCV is 
HCV has a high rate of genetic heterogeneity, 
therefore, no vaccine or immunoglobulin exist to 
prevent this infection[18]. Recent advances in HCV 
therapy have led to the development of new antiviral 
drugs for treatment of HCV infection, including the 
protease inhibitors telaprevir, simeprevir, boceprevir, 
and paritaprevir; NS5A inhibitors ledipasvir, daclatasvir, 
and ombitasvir; the nucleotide analog NS5B polymerase 
inhibitor sofosbuvir; and the non-nucleotide polymerase 
inhibitor dasabuvir[8,19,20]. These new therapies are 
well-tolerated and safer and much more effective 
than the previous therapies pegylated interferon 
(IFN)/ribavirin[20]. Despite these advantages, pegylated 
IFN-α in combination with ribavirin is recommended as 
the standard treatment for HCV infection in Iran[21-24]. 
The reasons for this are the high cost and restricted 
availability of the new medications in low- and middle-
income countries[25]. 
Iran is a vast country with various ethnicities in 
different provinces. This country, with an area of about 
1700000 km2, is located in the Middle East between 
Arab peninsula, Indian subcontinent, Europe, and 
Middle Asia[26,27]. There are variations in the prevalence 
and epidemiology of HCV in different groups and 
regions throughout the country. To achieve better 
strategies for the prevention and management of 
HCV infection, the current knowledge regarding the 
epidemiology of HCV infection merits reviewing. 
Therefore, we present here a clear review about the 
current epidemiology of HCV in Iran.
HCV IN BLOOD DONORS
In Iran, the prevalence of HCV infection among 
blood donors in different studies varies considerably, 
depending on the study population, sample sizes, 
study periods, the geographic regions, risk factors, 
and the methods and type of kits used to determine 
HCV[15,28]. According to the results of a meta-analysis 
study, the prevalence of anti-HCV among 10739221 
blood donors was 0.5% during 1996 to 2011[28]. In 
another study, the rate of anti-HCV seropositivity 
among 6499851 blood donors was 0.13% during 
2004 to 2007[29]. The highest anti-HCV prevalence of 
1.39% was declared in 2005, followed by a significant 
decreasing rate from 0.13% in 2007 to 0.03% in 
2009[4,28]. The reasons for this decline were the 
implementation of more restrictive rules in physical 
examination prior to donation and the application of 
more sensitive HCV test kits for screening the blood 
by Iran Blood Transfusion Centers[27,28]. In addition, 
the public has become more aware of the routes of 
transmission of HCV infection in recent years[29]. 
Iran has the lowest anti-HCV prevalence among 
blood donors compared to corresponding figures in the 
Middle East countries, such as 0.6% in Lebanon, 0.8% 
in Kuwait, 0.9% in Oman, 2.7% in Yemen, and 5%-25% 
in Egypt[4,27,28,30,31]. Globally, however, the lowest HCV 
prevalence of 0.01%-0.1% has been reported in the 
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changing in Iran. Therefore, this review was conducted 
to present a clear view about current epidemiology of 
HCV in Iran.
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INTRODUCTION
Hepatitis C virus (HCV) is a small, enveloped positive-
stranded RNA virus, belonging to the family Flaviviridae 
and the genus Hepacivirus[1,2]. Based on genomic 
heterogeneity, HCV has been classified into seven 
genotypes and over 70 different subtypes[3,4]. HCV is 
transmitted through exposure to infected blood and 
blood products. Blood transfusion, injecting drug use, 
sexual intercourse, surgery, and tattooing are some 
possible ways to spread HCV infection[5,6]. Among 
these, HCV transmission by sexual intercourse is less 
common and includes those that lead to mucosal 
exposure to infectious blood or blood-derived body 
ﬂuids and is related to the presence of mucosal tears 
and genital ulcerative disease[7,8].
HCV is the major cause of chronic liver disease, 
and can lead to cirrhosis and hepatocellular carcinoma 
(HCC)[3,9]. Although the infection is preliminary 
acute with a wide spectrum of clinical manifestations 
from asymptomatic to mild or even severe clinical 
illness[10], about 75% to 85% of acute HCV infections 
slowly progress to chronic infection[11]. Approximately 
10%-20% of those chronically infected are at risk of 
developing liver cirrhosis within 20 to 30 years, and 
of those with cirrhosis, 1%-5% per year will develop 
HCC[12].
HCV infection is defined as the presence of 
HCV-RNA and anti-HCV antibodies in serum or 
plasma. A positive HCV antibody test [enzyme linked 
immunosorbent assay (ELISA) and immunoblot 
assay] indicates exposure to HCV, however, it cannot 
distinguish between current or past infection. In 
general, anti-HCV antibody positive samples can be 
defined as current HCV infection if the HCV RNA test 
[reverse transcriptase polymerase chain reaction 
(RT-PCR)] is positive[8,13]. 
According to the World Health Organization 
reports, about 130-150 million of the world population 
have chronic HCV infection[14]. In addition, 3-4 
million new cases of HCV infection emerge globally 
each year[15,16]. The chronic infection might result in 
cirrhosis, hepatic failure, or HCC, which are responsible 
for approximately 350000 to 500000 deaths per 
year[5,14,17,18]. Therefore, HCV is a life threatening 
global health problem, and its prevention is the main 
objective. 
United Kingdom and Scandinavia[5,18,32-34]. 
At present, the ELISA and confirmatory recom-
binant immunoblot assay (RIBA) are used routinely 
for screening of the blood donors by the Iranian blood 
bank transfusion centers. It seems screening of blood 
is an important factor in controlling and reducing 
the rate of HCV infection in the general population. 
However, the presence of asymptomatic or occult HCV 
infected donors with no detectable HCV Ab or low copy 
number of HCV genomes in their blood is a potential 
source of HCV transmission. Thus, the risk of HCV 
transmission through blood transfusion is considered 
an important public health concern[28,35] (Table 1[35-56]). 
HCV IN GENERAL POPULATION
With an overall anti-HCV prevalence of less than 1% 
in the general population, Iran is considered a country 
with low frequency HCV infection[27]. However, it 
seems the prevalence of HCV is slightly rising in the 
country[57,58]. The prevalence of HCV infection in the 
general population varies considerably in different 
regions of Iran (Table 2[58-68]). These variations in the 
prevalence of HCV might be due to the differences in 
the quality of public health services, lifestyles, habits, 
and rates of high-risk behaviors in different geographic 
regions[15,28].
In Iran, the prevalence of HCV infection in the 
general population is lower than those of the neigh-
boring countries such as Afghanistan (1.1%), Turkey 
(1%-2.1%), Pakistan (4.7%), Iraq (7.1%), and Qatar 
(6.3%)[4,30]. Globally, the highest HCV prevalence of 
17.5% (13%-22%) has been reported in Egypt[59]. 
The general population-based prevalence of HCV 
infection is used to describe and compare the local and 
global epidemiology of HCV infection[10,16]. The surveys 
on prevalence of HCV in the blood donor population fail 
to assess the true prevalence in an entire community. 
Since a large number of HCV positive cases are 
excluded from donating blood, the donor population 
is representative of a population at low risk of HCV 
infection. A recent study reported a HCV prevalence 
of 9.2% in the excluded individuals[27]. Therefore, the 
prevalence of HCV in the general population is higher 
than that in the donor population[27,28]. 
HCV IN HIGH-RISK GROUPS
HCV in intravenous drug users
Presently, injecting drug use is the main route of HCV 
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Table 1  Prevalence of hepatitis C virus among blood donors in Iran
Author Year of study City or province Location No. of 
participants
No. of positive 
samples
Prevalence Test Ref.
Taheri Azbarmi 2003-2005 Rasht, 
Gilan province
North     49820       91 0.18% ELISA and RIBA [36]
Mansour-Ghanaei 1998-2003 Gilan North   221508   3603 1.62% ELISA [37]
    709 0.32% RIBA
Bani Aghil 2006-2008 Golestan North-East   128198     161 0.12% ELISA and immunoblot [38]
Khedmat 2003-2005 Tehran North-Center 1004889 21390 2.10% ELISA [39]
  1005 0.10% RT-PCR
Attarchi 2003-2004 Tehran North-Center     26645       42 0.20% ELISA and RIBA [40]
Khedmat 2005-2006 Tehran North-Center   318029     323 0.09% ELISA, immunoblot and 
RT-PCR
[35]
Bozorgi 2002-2004 Qazvin West-Center     48116       73 0.15% ELISA and RIBA [41]
Mahdaviani 2004 Arak West-Center     11615       81 0.70% ELISA [42]
      33 0.20% RIBA
Bozorgi 2009 Qazvin West-Center     20591     328 1.59% ELISA [43]
      35 0.17% HCV conﬁrmatory tests 
(ND)
Afzali 1996-2001 Kashan Center     43731     477 1.10% ELISA [44]
Moniri 2001-2002 Kashan Center         600         3 0.50% ELISA [45]
Karimi 2004-2006 Shahr-e Kord Central     35124       70 0.20% ELISA and immunoblot [46]
Masaeli 2002-2003 Isfahan Center     29458       24 0.27% ELISA and RIBA [47]
Esmaieli 2006-2007 Bushehr South     20294       42 0.20% ELISA and immunoblot [48]
Ghavanini 1998 Shiraz South       7897       47 0.59% ELISA and immunoblot [49]
Emamghorashi 2001-2003 Jahrom South       3000         9 0.30% ELISA and immunoblot [50]
Kasraian 2002-2005 Shiraz South   507531     710 0.14% ELISA [51]
Kasraian 2007-2008 Shiraz South     93987     203 0.21% ELISA and RIBA [52]
Delavari 2003 Kerman South-East     15252       60 0.39% ELISA [53]
Tajbakhsh 2004 Shahr-e kord West     11472       69 0.60% ELISA [54]
Doosti 2003-2004 Shahrekord West     11200       76 0.67% ELISA [55]
0.59% immunoblot
0.41% RT-PCR
Ghafouri 2006-2009 South Khorasan East     42652       31 0.07% ELISA [56]
      13 0.03% RIBA
ND: Not deﬁned; ELISA: Enzyme linked immunosorbent assay; RT-PCR: Reverse transcriptase polymerase chain reaction; RIBA: Recombinant immunoblot 
assay.
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abusers and about 180000 (12.2%) of this population 
are injecting drug users (IDUs)[9]. Estimates from Iran 
show a HCV prevalence of 50%-75% among IDUs[6]. 
transmission[6,9,69]. Iran has one of the highest numbers 
of drug addicts in the world[9,70]. It has been reported 
that 2.8% of Iranian adults aged 15-64 years are drug 
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Table 2  Prevalence of hepatitis C virus among general population in Iran
Author Year of study City or province Location No. of 
participants
No. of positive 
samples
Prevalence Test Ref.
Zamani 2008-2011 Amol, Mazandaran North 6145 12 0.20% ELISA [60]
  5 0.08% RIBA
  3 0.05% RT-PCR
Mansour-Ghanaei 2003 Gilan North   383   9 2.30% ELISA [61]
  5 1.30% RT-PCR
Shakeri 2010-2011 Mashhad North-East 3870   8 0.20% ELISA [62]
  5 0.13% RT-PCR
Ghadir 2006 Golestan North-East 2123 56 2.60% ELISA [63]
22 1.00% RIBA
Merat 2006 Golestan North-East 1895 18 1.00% ELISA and RIBA [58]
Merat 2006 Tehran North-Center 2326   8 0.30% ELISA and RIBA [58]
Merat 2006 Hormozgan South 1463 24 1.60% ELISA and RIBA [58]
Motlagh 2001 Ahvaz South-West     80   5 6.25% ELISA [64]
  0 0.00% Immunoblot
Nikbakht 2007-2008 Ahvaz South-West   712   9 0.63% ELISA [65]
Moradi 2001-2002 Saravan, South-East   365   3 0.80% ELISA [66]
Sistan and
Baluchestan
Sayad 2006 Kermanshah West 1721 15 0.87% ELISA, immunoblot 
and RT-PCR
[67]
Mohebbi 2007-2008 Lorestan West   827   2 0.20% ELISA [68]
Table 3  Prevalence of hepatitis C virus among injecting drug users in Iran
Author Year of 
study
City or province location No. of participants No. of positive 
samples
Prevalence Test Ref.
Mohtasham Amiri 2003 Gilan North     81   72 88.9% ELISA [72]
Rahimi-Movaghar 2006-2007 Tehran North-Center   895 309 34.5% ELISA [73]
Hosseini 2006 Tehran North-Center   417 334 80.0% ELISA [74]
Zali 1995 Tehran North-Center 402 (Male imprisoned 
IDUs)
182 45.3% ELISA, RIBA [75]
Zamani 2004 Tehran North-Center   202 105 52.0% Particle 
Agglutination (PA) 
assay
[76]
Hajinasrollah 2005 Tehran North-Center     65   11 17.0% ELISA [77]
Amin-Esmaeili 2006-2007 Tehran North-Center   895 309 34.5% ELISA [78]
Nokhodian 2008-2009 Isfahan Center   531 250 47.1% ELISA [79]
Zamani 2008 Isfahan Center   117   71 60.7% EIA [80]
Kassaian 2009 Isfahan Center   943 392 41.6% ELISA [81]
Fadaei Nobari 2011 Isfahan Center 1747 595 34.0% ELISA [82]
Soﬁan 2009 Arak, Markazi West-Center 153 (Male IDUs)   91 59.5% ELISA [83]
Ramezani 2012 Arak West-Center 100 (Male IDUs)   56 56.0% ELISA [84]
Honarvar 2012-2013 Shiraz South 569 (High risk groups) 109 19.1% ELISA and 
immunoblot
[70]
233 (IDUs)   94 40.3%
336 (non-IDUs)   15   4.4%
Davoodian 2002 Bandar Abbas, 
Hormozgan
South 249 163 64.8% ELISA [85]
Sarkari 2009-2010 Kohgiloyeh and 
Boyerahmad
South-West 158   67 42.4% ELISA [86]
Imani 2004 Shahr-e Kord Sout-West 133   15 11.3% ELISA [87]
Alavi 2002-2006 Ahvaz South-West 333 103 30.9% ND [88]
Mohammad Alizadeh 2002 Hamadan West 149 (IDUs Prisoners)   47 31.5% ELISA, immunoblot [89]
Keramat 2005-2007 Hamadan West 379 (High risk groups) 135 35.6% ELISA, immunoblot [90]
199 (IDUs) 126 63.3%
IDUs: Injecting drug users; ND: Not deﬁned; ELISA: Enzyme linked immunosorbent assay; RIBA: Recombinant immunoblot assay.
Taherkhani R et al . HCV in Iran
ELISA: Enzyme linked immunosorbent assay; RT-PCR: Reverse transcriptase polymerase chain reaction; RIBA: Recombinant immunoblot assay.
However, the prevalence of anti-HCV among IDUs 
varies considerably in different regions of Iran (Table 
3[70-90]). The outcomes revealed that Gilan, Hamedan, 
Tehran, and Hormozgan provinces have the highest 
rate of HCV infection, while Shahre Kord had the 
lowest rate of infection (Table 3). As a result, IDUs are 
the main source of HCV infection in Iran and account 
for the large proportion of current HCV transmission 
in the society[6,9,27]. In addition, the prevalence of HCV 
infection in prisons of Iran is extremely high, where 
38% to 90% of imprisoned IDUs have been infected 
with HCV[9]. Interestingly, tattooing more effectively 
transmits HCV infection than injecting drug use among 
Iranian prisoners[6]. 
The global prevalence of HCV infection among 
IDUs varies considerably from 9.8% to 97.4%[71]. 
Approximately 10 million IDUs with a global midpoint 
prevalence of 67% are positive for anti-HCV. The 
highest rate of HCV infection among the IDUs has 
been reported in China (67%, 1.6 million), the United 
States (73.4%, 1.5 million), and Russia (72.5%, 1.3 
million)[71].
HCV in hemodialysis patients
Distribution of HCV infection among hemodialysis 
patients has a vast geographic variation in different 
regions of Iran (Table 4[91-119]). According to a recent 
meta-analysis study in Iran, prevalence of HCV 
infection among this group of patients was reported 
to be 13.6%, 12.2%, and 7.6% by ELISA, RIBA, and 
PCR, respectively, which is lower than those of Saudi 
Arabia (50.5%), Kuwait (43.4%), Jordan (32.5%), 
and Pakistan (23.7%)[91-94] but higher than those of 
Australia (2.3%), United Kingdom (2.7%), Germany 
(3.9%), and Bahrain (7.4%)[95-97]. The risk of HCV 
infection is extremely high among hemodialysis 
patients[11]. Recent surveys show that the prevalence 
of HCV infection among hemodialysis patients is not 
related to history of blood transfusion. Considering the 
fact that the length of time on dialysis is significantly 
associated with HCV seropositivity, the nosocomial 
transmission is the main route of HCV transmission 
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Table 4  Prevalence of hepatitis C virus among hemodialysis in Iran
Author Year of study City or province Location No. of 
participants
No. of positive 
samples
Prevalence Test Ref.
Makhlough 2006 Mazandaran North 186   39 21.0% ELISA [99]
  21 11.3% RT-PCR
Amiri 2001 Gilan North 298   80 26.8% ELISA [100]
  74 24.8% Immunoblot
Joukar 2008 Gilan North 514   61 11.9% ELISA [101]
  32   6.2% RT-PCR
Samimi-rad 2005 Markazi West-Center 204   11   5.4% ELISA, RIBA and 
RT-PCR
[102]
Bozorghi 2006 Qazvin West-Center   89     9 10.3% ELISA [103]
    6   6.4% RIBA
Somi 2012 Tabriz North-West 455   37   8.1% ELISA [104]
Zahedi 2010 Kerman South-East 228   16   7.0% ELISA [105]
    7   3.0% PCR
Kalantari 2010-2011 Isfahan Center 499   26   5.2% ELISA [106]
Zamani 1998–2005 Amol, Tonekabon, 
Rasht and Ramsar
North 334   67 20.0% ELISA, RT-PCR [107]
Mazandaran and 
Gilan provinces
Assarehzadegan 2005-2006 Khuzestan South-West 214   34   7.9% ELISA, RT-PCR [108]
Nemati 1990-2006 Tehran Center 112     6   5.3% ELISA, RT-PCR [109]
Sotoudehjahromi 2006 Jahrom South   34     3   8.8% ELISA [110]
    2   5.9% RIBA
Alavian 2003 Tehran North-Center 838 176 21.0% ELISA [111]
111 13.2% RIBA
Broumand 2002 Tehran North-Center 548 105 19.6% ELISA [112]
  51 9.33% RT-PCR
Nasiri-Toosi 2007 Tehran North-Center 130   11   8.5% ND [113]
Mohammad-Alizadeh 2002 Hamedan West   96     9 11.4% ELISA [114]
Saboor 1999-2000 Kermanshah West 140   37 26.4% ELISA [115]
Jabbari 2008 Golestan North-East   93   23 24.7% ELISA, RIBA [116]
Ansari 2005-2006 Urmia North-West   50   19 38.0% EIA [117]
  12 24.0% RT-PCR
Hassanshahi 2006-2007 Kerman South-East 203   64 31.5% ELISA, RT-PCR [118]
Ansar 1997-1998 Gilan North   93   52 55.9% ELISA [119]
ND: Not deﬁned; ELISA: Enzyme linked immunosorbent assay; RT-PCR: Reverse transcriptase polymerase chain reaction; RIBA: Recombinant immunoblot 
assay.
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among Iranian hemodialysis patients[11,98].
HCV in hemophilia patients
Hemophilia patients may acquire HCV infection 
via contaminated blood products[98]. In Iran, the 
prevalence of HCV among hemophilia patients is very 
high, with an overall prevalence of 40.8%[98] and has 
a wide geographic variation (Table 5[120-134]). Most 
of the HCV infections among hemophilia patients 
are asymptomatic and may lead to liver failure. 
Therefore, routine screening for HCV infection in 
hemophilia patients is required to prevent the serious 
consequences of HCV infection[27].
HCV in thalassemia patients
HCV is a major cause of mortality in thalassemia 
patients due to post-transfusion HCV infection, 
which dramatically progresses to liver failure or 
even HCC[27,135]. Therefore, HCV infection is currently 
considered the main health problem in thalassemia 
patients, and much more attention to HCV screening 
in the blood transfusion process may improve survival 
of thalassemia patients[136]. Even though the current 
policies of blood banks have considerably decreased 
the incidence of HCV infection in thalassemia patients, 
blood transfusion remains the main risk factor for HCV 
infection among this group of patients because of 
transfusion of HCV-infected seronegative blood donated 
during the window period[27,136,137]. Therefore, the rate of 
HCV infection is high among thalassemia patients[137]. 
The geographical distribution of HCV infection 
among thalassemia patients varies widely in different 
regions of Iran (Table 6[86,118,119,127-129,137-151]), but a 
recent meta-analysis study reported the overall HCV 
prevalence is 18% among thalassemia patients in 
Iran[136]. Iran has the lowest rate of HCV infection 
among thalassemia patients in comparison with 
Eastern Mediterranean countries[136]. High prevalence 
of HCV infection has been reported among thalassemia 
in Egypt (69%), Saudi Arabia (63%), and Pakistan 
(45%)[136]. 
HCV in health care workers
Health care workers are at the risk of acquiring HCV 
infection due to occupational exposures to blood and 
blood-derived body ﬂuids[152]. There are few reports 
on the prevalence of HCV infection among health care 
workers in Iran. In Shoaei et al[153], HCV infection 
status was negative in 203 health care workers in 
Isfahan city in 2012. Similarly, all 191 health care 
workers were tested negative for HCV antibodies in 
Shahrud province in 2010[154]. Hadadi et al[155] reported 
a HCV prevalence of 6.6% (31/467) among health 
care workers in Tehran in 2004-2005, and Sarkari 
et al[86] reported a HCV seroprevalence of 4.2% 
among 212 health care workers in Kohgiloyeh and 
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Table 5  Prevalence of hepatitis C virus among hemophilia patients in Iran
Author Year of study City or province Location No. of 
participants
No. of positive 
samples
Prevalence Test Ref.
Mansour-Ghanaei 1999 Gilan North   101   72 71.30% RIBA [120]
Torabi 2004 East Azarbaijan North-West   130   72 56.00% ELISA, RIBA [121]
Valizadeh 2010 West Azarbaijan North-West     35     3 8.57% ELISA, RIBA 
and RT-PCR
[122]
Mousavian 2003-2005 Tehran North-Center 1095 802 72.30% ELISA and RT-
PCR
[123]
Kalantari 2008-2010 Isfahan Center   615 495 80.50% ELISA [124]
347 56.40% RT-PCR
Mobini 2006 Yazd Center     77   41 53.20% ELISA [125]
  38 49.40% RT-PCR
Yazdani 1996-2010 Isfahan Center   350 231 66.00% ELISA [126]
Javadzadeh 
Shahshahani
2003 Yazd Center     74   36 48.60% ELISA and 
RIBA
[127]
Samimi-Rad 2004 Markazi West-Center     76   34 44.70% ELISA [128]
  33 43.40% RIBA
  23 30.26% RT-PCR
Mahdaviani 2004 Markazi West-Center     68   26 38.20% ELISA [129]
  25 36.70% RIBA
Karimi 1999-2000 Shiraz South   281   44 15.65% ELISA and 
immunoblot
[130]
Assarehzadegan 2008-2009 Ahvaz South-West     87   47 54.00% ELISA [131]
  42 48.30% RT-PCR
Zahedi 2002 Kerman South-East     97   43 44.30% ELISA and 
RIBA
[132]
Shariﬁ-Mood 2003-2006 Zahedan, 
Sistan and Baluchistan
South-East     81   24 29.60% ELISA and 
immunoblot
[133]
Esfahani 2012 Hamadan West     89   44 49.40% ELISA [134]
  15 16.70% RT-PCR
Taherkhani R et al . HCV in Iran
ELISA: Enzyme linked immunosorbent assay; RT-PCR: Reverse transcriptase polymerase chain reaction; RIBA: Recombinant immunoblot assay.
Boyerahmad province in 2009-2010.
The global prevalence of HCV infection among 
health care workers is 1%-6%[156]. After HBV, HCV is 
the most common blood-borne infection found among 
health care workers. Needle-stick or sharp injuries and 
mucosal exposure following blood splash are the most 
common risk factors for HCV infection among health 
care workers[152,153]. Therefore, prevention strategies 
and training programs are needed for health care 
workers to reduce the incidence of HCV infection in this 
group.
HCV in homeless people
Homeless people are one of the main high-risk groups 
for acquiring HCV infection because of high-risk 
behaviors, lifestyle, low levels of education, poverty, 
and poor hygiene[157,158]. There are over 100 million 
homeless people worldwide, and the prevalence of HCV 
infection among this group varies from 3.9% to 36.2% 
in different parts of the world[159]. Currently, there are 
no data on the number of homeless people in Iran, 
and only a few studies are available on the prevalence 
of HCV infection among homeless people in Tehran, 
the capital of Iran. Amiri et al[157] reported a HCV 
prevalence of 23.3% among 593 homeless individuals 
in Tehran in 2012. In another study by Vahdani et 
al[158], the prevalence of HCV infection was found to 
be 42.8% among 202 homeless men in Tehran city 
in 2007. According to the available data in Iran, the 
prevalence of HCV infection is considerably high among 
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Table 6  Prevalence of hepatitis C virus among thalassemia patients in Iran
Author Year of study City or province Location No. of participants No. of positive 
samples
Prevalence Test Ref.
Mirmomen 2002 Tehran North-Center 410   80 19.6% ELISA, RIBA [138]
Kerman South-East 100   18 18.8%
Qazvin West-Center   95   23 25.3%
Semnan East-Center   81   19 24.4%
Zanjan West   46     1   2.2%
Total 732 141 19.6%
Ansar 1997-1998 Rasht North 105   67 63.8% ELISA [119]
Ghane 2010-2011 Gilan and 
Mazandaran
North 245   46 18.8% ELISA [139]
  28 11.4% Nested-PCR
Tamaddoni 2005 Babol North 113   12 10.6% ELISA [140]
Mansouritorghabeh 2007 Mashhad North-East 360   30 8.33% ELISA [137]
Alavi ND Tehran North-Center   90 
(pediatric patients)
  12 13.3% ELISA, RT-PCR [141]
Alavian 2002 Qazvin West-Center   96   23 24.2% ELISA, RIBA [142]
Samimi-Rad 2004 Markazi West-Center   98     7   7.1% ELISA [128]
    5   5.1% RIBA
    2   2.04% RT-PCR
Bozorgi 2005 Qazvin West-Central 207   54   26.1% ELISA [143]
  50 24.01% RIBA
Azarkeivan 1996-2009 Tehran North-Center 395 109 27.5% EIA, RIBA [144]
Mahdaviani 2004 Markazi West-Center   97     9   9.2% ELISA [129]
    7   7.2% RIBA
Nakhaie 1999-2000 Tehran North-Center 507 122 24.0% ELISA [145]
  41   8.1% RT-PCR
Kalantari 2008-2010 Isfahan Center 545   50   9.1% ELISA [124]
  31   5.6% RT-PCR
Ataei 1996-2011 Isfahan Center 466   37   8.0% ND [146]
Javadzadeh 
Shahshahani
2003 Yazd Center   85     8   9.4% ELISA, RIBA [127]
Karimi 1999-2000 Shiraz South 466 
(pediatric patients)
  73 15.7% ELISA and 
immunoblot
[147]
Kashef 2006 Shiraz South 131   24 18.3% ELISA and 
immunoblot
[148]
    7   5.3% RT-PCR
Kadivar 1999 Shiraz South 147   40 27.2% ELISA [149]
Shahraki 2005-2007 Zahedan South-East 560 
(pediatric patients)
  30   5.3% ELISA [150]
  20   3.5% PCR
Hassanshahi 2006-2007 Kerman South-East 181   81 44.7% ELISA, RT-PCR [118]
Ghafourian 
Boroujerdnia
2005-2006 Ahvaz South-West 206   58 28.2% ELISA [151]
  46 22.3% RT-PCR
Sarkari 2009-2010 Kohgiloyeh and 
Boyerahmad
South-West   49     3   6.1% ELISA [86]
ND: Not deﬁned; ELISA: Enzyme linked immunosorbent assay; RT-PCR: Reverse transcriptase polymerase chain reaction; RIBA: Recombinant immunoblot 
assay.
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the older homeless population and homeless IDUs, 
especially those with a history of imprisonment[157,158]. 
The seroprevalence of HCV was reported to be 3.5% 
among the street children in Tehran city in 2008[160], 
while it was 1.0% in Isfahan city in 2005-2007[161].
The prevalence of HCV infection among homeless 
populations is higher than the other blood-borne 
infections, therefore, HCV infection is the main health 
problem among homeless population of Iran and 
implementation of HCV-controlling and educational 
programs are required to reduce HCV infection among 
this population[157,158,161].
HCV in human immunodeficiency virus-positive patients
Prevalence of HCV coinfection among human immuno-
deficiency virus (HIV) positive patients ranges from 
11.5% to 94.0% in different regions of Iran[85,162] (Table 
7[85,162-174]). This geographic variation in HCV/HIV 
coinfection reflects diversity of the risk factors, the 
types of exposure, and the epidemiology of these 
viruses in different regions of the country[163,164]. 
However, in all of these studies, intravenous drug use 
and a history of imprisonment were the most prevalent 
risk factors for HCV/HIV co-infection in Iran[164-169].
The prevalence of HCV coinfection is noticeably high 
among HIV-positive patients in Iran. The shared modes 
of transmission and the lack of an effective vaccine 
for HCV could explain this high prevalence[163-165,169,170]. 
In Iran, HCV and HIV are predominantly transmitted 
by injecting drug use[165,170,171]. Moreover, the rate of 
IDUs is increasing in Iran, which may boost the rate of 
HCV/HIV coinfection in the country[163]. 
HCV coinfection adversely affects HIV disease 
outcomes and leads to severe liver disorders, pro-
gression to cirrhosis and HCC, and subsequently lower 
survival of HIV infected patients[163-165]. HIV infection 
leads to higher rates of HCV persistence, increased 
risk of hepatotoxicity due to the extensive use of 
anti-retroviral drugs, and subsequently accelerated 
end stage liver disease[164,169-171]. Overall, one third 
of mortalities in HIV infected patients are related to 
liver diseases[163,164,170]. Therefore, HCV coinfection is 
considered a potential threat to HIV positive patients, 
and routine screening for HCV infection, as well as HCV 
treatment, seem to be necessary in all HIV-positive 
patients[164,165,169,172].
HCV IN IMMUNOLOGICAL DISORDERS
HCV in patients with mixed cryoglobulinemia
Mixed cryoglobulinemia is the most common immu-
nological disorder reported in patients with chronic 
HCV infection[175-177]. The prevalence of HCV infection 
in patients with mixed cryoglobulinemia ranges from 
40% to 90% worldwide[178]. Several studies have 
reported HCV infection as the etiological agent of 
mixed cryoglobulinemia[176,179,180]. Gharagozloo et 
al[181] reported an anti-HCV prevalence of 69% among 
patients with mixed cryoglobulinemia in Iran. In Owlia 
et al[182], 16% of patients (8/50) with HCV infection 
had cryoglobulins in central regions of Iran. However, 
this rate was relatively low in comparison with the high 
incidence of mixed cryoglobulinemia (19%-> 50%) 
among patients with chronic HCV infection.
HCV in patients with diabetes mellitus
Diabetes mellitus is one of the most prevalent 
metabolic disorders, and it affects 4.6%-10.0% of the 
Iranian population[183]. In 1994, a possible association 
between HCV infection and diabetes mellitus was 
first introduced[184]. Since then, many studies have 
demonstrated that HCV infection has a role in the 
activation of host innate immune responses and, via 
the TNF-α pathway, induces the destruction of insulin 
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Table 7  Prevalence of hepatitis C virus among HIV-positive patients in Iran
Author Year of study City or province Location No. of 
participants
No. of positive 
samples
Prevalence Test Ref.
Babamahmoodi 2008-2010 Mazandaran North     80     27   33.8% ELISA [173]
Ramezani 1999-2004 Tehran North-Center     95     65   68.0% ELISA [167]
SeyedAlinaghi 2004- 2005 Tehran North-Center   201   135   67.2% ELISA [170]
Ataei 1998-2007 Isfahan Center   130   100   77.0% ELISA and RIBA [168]
Davarpanah 2006-2007 Shiraz South   226   200   88.5% ELISA [166]
  196   86.7% RIBA
    59   26.1% RT-PCR
Khosravi Fars South   101     87   86.1% ELISA [172]
Alipour 2011 Shiraz South 1444 1132   78.4% ELISA [169]
Davoodian 2002 Bandar Abbas and 
Roodan
South     38     35   94.0% ELISA [85]
Zahedi 2011 Kerman South-East   165   122   73.9% ELISA [165]
Shariﬁ-Mood 2000-2005 Zahedan South-East     52       6   11.5% ND [162]
Alavi 2001-2003 Ahvaz South-West   104     77 74.04% ELISA [171]
Saleh 2013 Khorramabad, Lorestan West   103     23   22.3% ELISA [174]
Mohammadi 2007-2008 Lorestan West   391   282   72.0% ELISA [163]
ND: Not deﬁned; ELISA: Enzyme linked immunosorbent assay; RT-PCR: Reverse transcriptase polymerase chain reaction; RIBA: Recombinant immunoblot 
assay.
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signaling pathways and subsequently the development 
of insulin resistance[185]. In addition, immune-mediated 
pathogenesis or direct cytotoxic effects of HCV on 
pancreatic islet cells results in dysfunction of β cells and 
declines the insulin production[183,185-188]. Although HCV 
infects the pancreas, autoimmunity is not involved in 
the occurrence of diabetes[186].
Several studies have shown that the prevalence of 
HCV among diabetic patients is significantly higher than 
that in non-diabetic patients[187,189,190]. Interestingly, 
male gender, age over 40 years, and abnormal liver 
enzymes are associated with high prevalence of HCV 
infection among patients with diabetes mellitus[191]. 
Although there are several reports on the prevalence 
of HCV infection among patients with diabetes 
mellitus in Iran, the results show great heterogeneity. 
Aghamohammadzadeh et al[192] reported HCV 
seropositivity in 2.5% (10/400) of Iranian patients with 
diabetes mellitus in Tabriz. In addition, Alavian et al[193] 
showed an increased risk of diabetes mellitus among 
Iranian patients with chronic HCV infection in Tehran. 
While, Janbakhsh et al[194] reported no association 
between HCV infection and the occurrence of diabetes 
in Kermanshah. Metanat et al[195] found no association 
between HCV and diabetes in Zahedan, and Bahar et 
al[196] reported similar findings in Tehran.
According to the epidemiological data, patients 
with chronic HCV infection are at an increased risk for 
developing diabetes[191,197,198]. HCV infection is a risk 
factor for occurrence of diabetes, and diabetes will 
enhance the risk of liver fibrosis, cirrhosis, and finally 
progression to HCC[187]. Therefore, screening of all HCV 
positive patients for diabetes mellitus is recommended 
to reduce the adverse effects associated with diabetes 
on HCV infection, which may progress to liver fibrosis, 
cirrhosis, or even HCC.
The incidence of diabetes mellitus among HCV 
positive patients ranges from 23% to 62% in different 
parts of the world[183]. This incidence is 18.3% among 
Iranian HCV-infected patients, which is higher than 
that in the general population of Iran[183]. Compared 
to other parts of the world, the prevalence of diabetes 
mellitus among Iranian patients with HCV infection is 
low. Overall, there are no adequate studies in this field 
in Iran. Therefore, more surveys are recommended 
to clearly identify the frequency of diabetes mellitus 
among HCV-infected patients in Iran. 
HCV in patients with autoimmune thyroid disorders
Autoimmune thyroid disorders (ATD), including 
Hashimoto’s thyroiditis and Graves’ disease, are the 
most prevalent endocrine problems worldwide[199,200]. 
Many investigators have investigated the possible 
association between chronic HCV infection and 
autoimmune thyroiditis. However, the exact role of 
HCV infection in the development of autoimmune 
thyroiditis remains unclear[201]. Investigations have 
suggested several mechanisms, including the following: 
(1) Non-autoimmune-mediated pathogenesis through 
direct cytopathic effect of HCV on thyrocytes, which 
results in destruction of thyroid follicular cells[201]; 
(2) Autoimmune-mediated pathogenesis due to 
the presence of homologous amino acid sequences 
between viral proteins and thyroidal proteins or 
molecular mimicry and over activation of autoreactive 
T-cells and B-cells during HCV infection, which results 
in production of anti-thyroid antibodies[200-202]; and 
(3) The adverse effects of IFN-therapy on thyroid 
gland through immune stimulatory and direct effects 
of IFN on the thyrocytes, which ultimately results in 
destructive thyroiditis[199,201,203]. Therefore, monitoring 
thyroid function is recommended during IFN-therapy in 
patients with HCV infection[201,204]. 
There are limited reports on the significance of 
HCV infection in patients with ATD in Iran. Ziaee et 
al[204] reported thyroid dysfunction in 10.3% of patients 
with chronic HCV infection in Tehran in 2002-2003, 
while, Rahimi et al[205] found no relationship between 
chronic HCV infection and autoimmune thyroiditis 
in Kermanshah in 2010. Similarly, Jadali et al[206,207] 
reported no relationship between HCV infection and 
Hashimoto’s thyroiditis or Graves’ disease in Tehran 
in 2005. Still, more studies are recommended to 
generate a clear epidemiological pattern of HCV 
infection among patients with thyroid disorders in Iran.
HCV in patients with lichen planus
Lichen planus (LP) is a chronic inﬂammatory disease 
of the skin and mucous membranes with unknown 
etiology[199,208,209]. Chronic HCV infection appears to 
have a role in the pathogenesis of LP through induction 
of host immune responses and immune dysregulation 
in susceptible patients[200,210,211]. This mechanism 
was confirmed by the presence of HCV-RNA and 
HCV-specific T lymphocytes in the skin and mucous 
membrane specimens of patients with LP[200,209]. 
Another possibility is the effect of IFN-therapy in the 
development of LP in patients with HCV infection[209]. 
However, HCV replicates in skin and mucous lesions of 
patients with LP, but no direct cytotoxic effect of HCV 
on skin and mucosa cells could be proposed in the 
development of LP[209]. The majority of patients with 
LP have not been infected with HCV[212]. In addition, 
the incidence of LP among patients with chronic HCV 
infection was estimated about 5% (1%-6%)[199,209]. 
Therefore, it seems that HCV contributes to the 
development of LP, with some unknown underlying 
factors also involved in this process[210]. 
According to the epidemiological data, the preva-
lence of HCV among LP patients varies considerably 
from 4% to 62% in different parts of the world, 
where this prevalence is higher in HCV endemic 
countries[209,210]. There are limited reports on the 
prevalence of HCV among patients with LP in Iran. 
Rabiei et al[213] reported high prevalence of oral lichen 
planus (OLP) in HCV-infected patients (4.7%) compared 
10798 October 14, 2015|Volume 21|Issue 38|WJG|www.wjgnet.com
Taherkhani R et al . HCV in Iran
to the general population (0.5%-2.0%) and suggested 
an association between HCV infection and OLP in Gilan 
in 2002. Similary, Khatibi et al[214] reported a higher 
prevalence of OLP in HCV-infected patients (4%) than 
the general population in Tehran. In contrast, Rahnama 
et al[215] reported no association between LP and HCV 
in Kerman in 2005. Similarly, Taghavi Zenouz et al[216] 
found no relationship between LP and HCV in Tabriz 
in 2009, and Ansar et al[208] reported a similar result 
in Hamedan province in 2011. Overall, Petti et al[212] 
reported a weak association between HCV and OLP in 
Iranian population. Further investigations are needed 
to clearly identify the association between HCV and LP 
in Iran.
HCV IN MALIGNANCY
HCV in patients with B-cell non-Hodgkin’s lymphoma
HCV is not only primarily hepatotropic, but it can also 
affect lymphatic systems and lead to B cell lympho-
proliferative disorders such as non-Hodgkin’s lymphoma 
(NHL)[217]. Few studies have evaluated the relationship 
between HCV seropositivity and the incidence of NHL 
in Iran. Aledavood et al[218] reported low prevalence 
of HCV infection among patients with NHL (0.7%) 
compared to the general population (0.5%-1%) and 
found no relationship between HCV infection and NHL 
in Northeast of Iran in 2014. In contrast, Rezaeian et 
al[219] reported high prevalence of HCV in patients with 
NHL (15.7%) compared to the control group (0%) and 
suggested an association between HCV infection and 
NHL. Similarly, Rastin et al[217] found a HCV prevalence 
of 7.4% among patients with NHL in Mashhad city. NHL 
is prevalent worldwide and is the eighth and 11th most 
common cancer in males and females, respectively[220]. 
Although the exact risk factor for NHL has not yet been 
determined, it seems that HCV infection has a role in 
the pathogenesis of this lymphoproliferative disorder[178].
According to the results of a meta-analysis 
study, the global prevalence of HCV infection in NHL 
patients is approximately 15%, which is higher than 
the prevalence of HCV in general population (1.5%), 
suggesting a possible role of HCV infection in the 
development of NHL[221]. Although the role of other 
factors, such as genetic and environmental factors, 
should also be considered in the pathogenesis of NHL 
malignancy[217,221]. 
HCV in patients with HCC
HCC is the fifth most common malignancy and the 
second most fatal cancer, with approximately 600000 
deaths annually worldwide[222]. HBV and HCV infections 
account for 50% and 25% of global HCC cases, 
respectively. However, HCV infection is the most 
predominant cause of HCC in Japan and the United 
States[222]. Iran is considered a low endemic area for 
HCC, with less than five cases per 100000 persons 
annually[26,223]. Kerman province, located in Southeast of 
Iran, has a higher incidence of HCC compared to other 
provinces. This may be due to higher frequency of HBV 
and HCV infections in this part of the country[224]. 
In Hajiani et al[225]’s study, the seroprevalence of 
HBV and HCV infections among patients with HCC in 
southern Iran were 52.1% and 8.5%, respectively. 
They pointed out that the prevalence of HCV infection 
among HCC patients may be underestimated due to 
the potential contribution of occult HCV infection in 
the development of HCC. Therefore, the prevalence 
of occult HCV infection among patients with HCC 
should be investigated in future surveys. Ansari et 
al[135] found a very low incidence of HCC (0.6%) 
among thalassemia patients with HCV infection due 
to the anti-HCV treatment in this group of patients. In 
Iran, HCV is the second most common cause of HCC 
after HBV infection[26,223]. However, it is predicted that 
chronic HCV infection will replace HBV infection as the 
main cause of HCC in the future[26].
DISTRIBUTION OF HCV GENOTYPES IN 
IRAN
HCV genotypes differ in their nucleotide sequence and 
biological properties, such as pathogenicity, infectivity, 
antigenicity, response to antiviral therapy, mode of 
transmission, as well as geographical distribution 
and age-distribution[226,227]. Distribution of HCV 
genotypes is variable in different regions of Iran (Table 
8[101,102,128,131,228-251]). Subtypes 1a is more prevalent 
in southern and northern Iran, 3a is more prevalent 
in northern and central Iran, 1b is more prevalent in 
southern and western Iran, and genotype 2 is more 
prevalent in western regions of Iran[4,226,228]. Overall, 
the most frequent genotype in Iran is 1a, followed by 
3a and 1b[4]. 
Distribution of HCV genotypes in Iran is different 
from other Middle Eastern countries with predominant 
genotype 4, but it is similar to the pattern seen in 
North America, with predominant genotypes 1, 2, 
and 3[4]. Genotype 2 is generally uncommon in Iran, 
therefore, the genotypic pattern differs from the United 
States, Europe, and Asia but is similar to Pakistan and 
India, where genotype 2 is very rare[226,229]. Genotype 
4 is uncommon in Iran and only seen in special patient 
groups[226]. A similar pattern regarding genotype 4 is 
seen in Europe, the United States, and India. However, 
due to changes in immigration patterns, the prevalence 
of genotype 4 is increasing in western countries in 
recent years (Table 9)[4,229,230]. Overall, the worldwide 
distribution of HCV genotypes shows that the genotypes 
1, 2, and 3 have a global prevalence, while genotypes 4, 
5, and 6 have a restricted prevalence[4,226,229,231]. 
Different HCV genotypes may be associated with 
particular patient groups. Therefore, the genotypic 
patterns can be used to trace the routes of trans-
mission[4]. Genotype 1 is more prevalent among 
thalassemia, hemophilia, hemodialysis, and solid organ 
10799 October 14, 2015|Volume 21|Issue 38|WJG|www.wjgnet.com
Taherkhani R et al . HCV in Iran
10800 October 14, 2015|Volume 21|Issue 38|WJG|www.wjgnet.com
Ta
bl
e 
8
  
D
is
tr
ib
ut
io
n 
of
 h
ep
at
it
is
 C
 v
ir
us
 g
en
ot
yp
es
 a
m
on
g 
he
pa
ti
ti
s 
C
 v
ir
us
 -
in
fe
ct
ed
 p
at
ie
nt
s 
in
 I
ra
n 
 n
 (
%
)
St
ud
y 
gr
ou
p
C
it
y 
or
 
pr
ov
in
ce
Lo
ca
ti
on
Y
ea
r 
of
 s
tu
dy
Sa
m
pl
e 
si
ze
G
en
ot
yp
e 
1
G
en
ot
yp
e 
2
G
en
ot
yp
e 
3
G
en
ot
yp
es
 4
 
an
d 
5
M
ix
ed
 
ge
no
ty
pe
N
on
 t
yp
ab
le
M
et
ho
d
A
ut
ho
r
R
ef
.
Bl
oo
d 
do
no
rs
 
A
hv
az
So
ut
h-
W
es
t
20
07
-2
00
8
   
 4
5
   
  1
a:
 2
4 
(5
3.
3)
  3
a:
 2
1 
(4
6.
7)
RF
LP
Fa
rs
ha
dp
ou
r
[2
33
]
Bl
oo
d 
do
no
rs
Te
hr
an
N
or
th
-C
en
te
r
20
06
-2
00
8
  1
03
   
  1
a:
 5
3 
(5
1.
5)
  3
a:
 3
9 
(3
7.
9)
7 
(6
.8
)
T
yp
e-
sp
ec
iﬁ
c 
pr
im
er
s
Sh
ar
iﬁ
[2
34
]
 1
b:
 4
 (3
.9
)
G
en
er
al
 p
op
ul
at
io
n
Ir
an
Ir
an
20
00
-2
00
5
  1
16
   
  1
a:
 7
1 
(6
1.
2)
  3
a:
 2
9 
(2
5.
0)
RF
LP
A
m
in
i
[2
35
]
   
  1
b:
 1
6 
(1
3.
8)
G
en
er
al
 p
op
ul
at
io
n
Ir
an
Ir
an
20
04
-2
00
7
  2
06
   
   
 1
a:
 5
3 
(2
5.
73
)
   
 2
: 4
 (1
.9
5)
   
 3
a:
 9
6 
(4
6.
60
)
11
 (5
.3
4)
  6
 (2
.9
1)
PC
R 
ki
t
H
aj
ia
[2
36
]
   
   
 1
b:
 3
6 
(1
7.
47
)
G
en
er
al
 p
op
ul
at
io
n
Is
fa
ha
n
C
en
te
r
20
07
-2
00
9
   
 9
7
   
  1
a:
 2
9 
(2
9.
5)
  2
: 2
 (2
.0
)
  3
a:
 5
9 
(6
1.
2)
2 
(2
.0
)
PC
R 
ba
se
d 
ge
n
ot
yp
in
g 
ki
t
Za
rk
es
h-
Es
fa
ha
ni
[2
37
]
 1
b:
 5
 (5
.1
)
G
en
er
al
 p
op
ul
at
io
n
Za
nj
an
W
es
t
20
07
-2
01
3
N
D
   
1a
: 2
2.
05
%
2:
 5
.1
4%
3a
: 3
8.
26
%
4:
 4
.4
1%
4.
41
%
Li
PA
Es
m
ae
ilz
ad
eh
[2
38
]
   
1b
: 2
5.
73
%
G
en
er
al
 p
op
ul
at
io
n
Ya
zd
C
en
te
r
20
10
-2
01
3
  1
91
   
  1
a:
 7
4 
(3
8.
7)
  2
: 3
 (1
.6
)
   
 3
: 9
6 
(5
0.
3)
5 
(2
.6
)
PC
R 
ba
se
d 
ge
n
ot
yp
in
g 
ki
t
H
ad
in
ed
ou
sh
an
[2
39
]
   
1b
: 1
3 
(6
.8
)
G
en
er
al
 p
op
ul
at
io
n
M
as
hh
ad
N
or
th
-E
as
t
20
09
-2
01
0
  3
82
   
   
 1
a:
 1
47
 (3
9.
2)
2a
: 9
 (2
.4
)
  3
a:
 1
50
 (4
0.
0)
5:
 1
3(
3.
4)
G
en
ot
yp
e 
sp
ec
iﬁ
c 
pr
im
er
s
V
os
su
gh
in
ia
[2
40
]
   
 1
b:
 4
1(
10
.9
)
G
en
er
al
 p
op
ul
at
io
n
Te
hr
an
N
or
th
-C
en
te
r
20
07
22
31
   
   
 1
a:
 8
86
 (3
9.
7)
  3
a:
 6
13
 (2
7.
5)
33
 (1
.6
)
40
1 
(1
8.
0)
G
en
ot
yp
e 
sp
ec
iﬁ
c 
pr
im
er
s
K
ey
va
n
i
[2
41
]
   
   
 1
b:
 2
71
 (1
2.
1)
G
en
er
al
 p
op
ul
at
io
n
G
ol
es
ta
n
N
or
th
20
10
   
 7
7
   
  1
a:
 1
5 
(1
9.
5)
2a
: 2
 (2
.6
)
  3
a:
 1
2 
(1
5.
6)
4:
 6
 (7
.8
)
8 
(6
.5
)
G
en
ot
yp
e 
sp
ec
iﬁ
c 
pr
im
er
s
M
or
ad
i
[2
42
]
   
 1
b:
 1
5(
19
.5
)
  3
b:
 1
9 
(2
4.
7)
G
en
er
al
 p
op
ul
at
io
n
A
hv
az
So
ut
h-
W
es
t
20
09
   
 8
0
   
  1
a:
 4
3 
(5
3.
8)
  3
a:
 3
7 
(4
6.
2)
RF
LP
H
am
id
i-F
ar
d
[2
43
]
Th
al
as
se
m
ia
 
M
az
an
da
ra
n
N
or
th
20
09
-2
01
1
   
 3
4
   
   
 1
a:
 1
3 
(3
8.
24
)
   
 3
a:
 1
5 
(4
4.
12
)
  4
 (1
1.
76
)
  1
 (2
.9
4)
T
yp
e-
sp
ec
iﬁ
c 
p
ri
m
er
R
aﬁ
ei
[2
44
]
   
1b
: 1
 (2
.9
4)
Th
al
as
se
m
ia
M
az
an
da
ra
n 
an
d 
G
ui
la
n
N
or
th
20
10
   
 2
8
   
1a
: 9
 (3
2.
1)
  3
a:
 1
8 
(6
4.
3)
RF
LP
G
ha
ne
[2
45
]
 1
b:
 1
 (3
.6
)
Th
al
as
se
m
ia
Fa
rs
So
ut
h
20
09
-2
01
2
   
 3
8
   
   
 1
: 1
7 
(4
4.
7)
   
   
3:
 6
 (1
5.
8)
15
 (3
9.
5)
Re
al
-ti
m
e 
PC
R
Ja
m
al
id
ou
st
[2
31
]
H
ae
m
op
hi
lia
M
az
an
da
ra
n
N
or
th
20
09
-2
01
1
   
 3
3
   
  1
a:
 7
 (2
1.
21
)
   
 3
a:
 2
5 
(7
5.
76
)
  1
 (3
.0
3)
T
yp
e-
sp
ec
iﬁ
c 
p
ri
m
er
R
aﬁ
ei
[2
44
]
H
ae
m
op
hi
lia
Fa
rs
So
ut
h
20
09
-2
01
2
   
   
8
   
  1
: 5
 (6
2.
5)
   
   
3:
 1
 (1
2.
5)
  2
 (2
5.
0)
Re
al
-ti
m
e 
PC
R
Ja
m
al
id
ou
st
[2
31
]
H
ae
m
op
hi
lia
A
hv
az
So
ut
h-
W
es
t
20
08
-2
00
9
   
 4
2
   
  1
a:
 2
6 
(6
1.
9)
   
 3
a:
 5
 (1
1.
9)
G
en
ot
yp
e 
sp
ec
iﬁ
c 
pr
im
er
s
A
ss
ar
eh
za
de
ga
n
[1
31
]
   
  1
b:
 1
1 
(2
6.
1)
H
ae
m
op
hi
lia
 
M
ar
ka
zi
W
es
t-C
en
te
r
20
04
   
 2
2
   
  1
: 6
 (2
7.
3)
  2
: 1
 (4
.5
4)
   
 3
a:
 4
 (1
8.
2)
  6
 (2
7.
3)
Li
PA
Sa
m
im
i-R
ad
[1
28
]
   
1a
: 3
 (1
3.
6)
  1
b:
 2
 (9
.1
)
ID
U
s
M
az
an
da
ra
n
N
or
th
20
09
-2
01
1
   
 3
7
   
   
 1
a:
 1
1 
(2
9.
73
)
   
   
3a
: 5
 (1
3.
51
)
  1
1 
(2
9.
73
)
T
yp
e-
sp
ec
iﬁ
c 
p
ri
m
er
R
aﬁ
ei
[2
44
]
   
   
 1
b:
 1
0 
(2
7.
03
)
ID
U
s
Te
hr
an
N
or
th
-C
en
te
r
20
08
-2
00
9
   
 3
6
1a
: 9
 (2
5)
   
 3
a:
 2
1 
(5
8.
3 
)
T
yp
e-
sp
ec
iﬁ
c 
pr
im
er
s
Ra
nj
ba
r K
er
m
an
i
[2
46
]
   
1b
: 6
 (1
6.
7)
ID
U
s
Fa
rs
So
ut
h
20
09
-2
01
2
  5
50
   
   
   
1:
 2
83
 (5
1.
5)
  3
: 1
92
 (3
4.
9)
  8
 (1
2.
2)
67
 (1
2.
2)
Re
al
-ti
m
e 
PC
R
Ja
m
al
id
ou
st
[2
31
]
ID
U
s
Te
hr
an
N
or
th
-C
en
te
r
20
08
-2
00
9
   
 8
3
  1
a:
 3
5 
(4
2)
  3
a:
 4
8 
(5
8.
0)
Se
qu
en
ci
ng
Sa
m
im
i-R
ad
[2
47
]
H
ae
m
od
ia
ly
si
s
M
az
an
da
ra
n
N
or
th
20
09
-2
01
1
   
 3
1
   
  1
a:
 6
 (1
9.
36
)
   
 3
a:
 2
4 
(7
7.
42
)
  1
 (3
.2
2)
T
yp
e-
sp
ec
iﬁ
c 
p
ri
m
er
R
aﬁ
ei
[2
44
]
H
ae
m
od
ia
ly
si
s
M
ar
ka
zi
W
es
t-C
en
te
r
20
05
   
   
8
1a
: 4
 (5
0)
   
 3
a:
 1
 (1
2.
5)
4:
 2
 (2
5)
Li
PA
Sa
m
im
i-R
ad
[1
02
]
   
1b
: 1
 (1
2.
5)
H
ae
m
od
ia
ly
si
s
Fa
rs
So
ut
h
20
09
-2
01
2
   
   
6
   
  1
: 4
 (6
6.
7)
4:
 1
(1
6.
7)
  1
 (1
6.
7)
Re
al
-ti
m
e 
PC
R
Ja
m
al
id
ou
st
[2
31
]
Taherkhani R et al . HCV in Iran
re
ci
pi
en
t 
pa
tie
nt
s[
23
1]
. 
S
ub
ty
pe
 1
b 
is
 p
re
va
le
nt
 in
 in
di
vi
du
al
s 
w
ith
 a
 h
is
to
ry
 o
f 
ho
sp
ita
liz
at
io
n,
 s
ur
ge
ry
, 
bl
oo
d 
tr
an
sf
us
io
n,
 a
nd
 a
lc
oh
ol
 c
on
su
m
pt
io
n[
22
6]
. 
S
ub
ty
pe
 1
a 
is
 f
re
qu
en
tly
 
fo
un
d 
in
 in
fe
ct
io
n 
by
 b
lo
od
 a
nd
 b
lo
od
 p
ro
du
ct
s[
22
8]
. 
H
ig
h 
fr
eq
ue
nc
y 
of
 g
en
ot
yp
es
 3
a 
an
d 
1a
 a
re
 s
ee
n 
am
on
g 
ID
U
s 
in
 I
ra
n[
22
8]
, 
w
hi
ch
 is
 s
im
ila
r 
to
 t
he
 g
en
ot
yp
ic
 p
at
te
rn
 a
m
on
g 
ID
U
s 
in
 E
ur
op
e 
an
d 
th
e 
U
ni
te
d 
S
ta
te
s[
22
6]
. 
G
en
ot
yp
e 
4 
is
 f
ou
nd
 in
 p
at
ie
nt
s 
un
de
rg
oi
ng
 h
em
od
ia
ly
si
s 
an
d 
pi
er
ci
ng
[2
26
,2
28
] . 
Th
is
 m
ig
ht
 b
e 
du
e 
to
 c
om
m
un
ic
at
io
n 
by
 d
ia
ly
si
s 
du
rin
g 
th
e 
H
aj
j 
ce
re
m
on
y 
in
 S
au
di
 A
ra
bi
a[
4]
. 
Th
e 
m
ix
ed
 in
fe
ct
io
n 
w
ith
 t
w
o 
or
 m
or
e 
ge
no
ty
pe
s 
is
 m
or
e 
co
m
m
on
 in
 p
at
ie
nt
s 
w
ith
 h
em
op
hi
lia
 a
nd
 t
ha
la
ss
em
ia
 a
nd
 m
ay
 le
ad
 t
o 
ch
ro
ni
c 
in
fe
ct
io
n,
 m
or
e 
se
ve
re
 d
is
ea
se
, r
e-
in
fe
ct
io
n,
 a
nd
 p
oo
r 
re
sp
on
se
 t
o 
th
er
ap
y[
2,
4]
. 
Th
er
e 
ha
s 
be
en
 a
 s
hi
ft
 i
n 
th
e 
di
st
ri
bu
tio
n 
pa
tt
er
n 
of
 H
C
V
 g
en
ot
yp
es
 o
ve
r 
tim
e[
4,
6,
23
2]
. 
G
en
ot
yp
e 
1a
 i
s 
th
e 
m
os
t 
pr
ev
al
en
t 
ge
no
ty
pe
 i
n 
Ir
an
, 
bu
t 
in
 r
ec
en
t 
ye
ar
s,
 a
n 
in
cr
ea
se
 in
 t
he
 f
re
qu
en
cy
 o
f 
3a
 a
nd
 a
 d
ec
re
as
e 
in
 1
a 
an
d 
1b
 h
av
e 
be
en
 r
ep
or
te
d 
am
on
g 
H
C
V
-i
nf
ec
te
d 
pa
tie
nt
s 
in
 I
ra
n.
 G
en
ot
yp
e 
1 
w
ith
 s
ub
ty
pe
s 
1a
 a
nd
 1
b 
ar
e 
m
or
e 
pr
ev
al
en
t 
in
 o
ld
er
 p
at
ie
nt
s 
an
d 
ge
no
ty
pe
 3
a 
in
 y
ou
ng
er
 p
at
ie
nt
s 
an
d 
ID
U
s[
4,
22
8,
23
2]
. 
Th
er
ef
or
e,
 i
t 
se
em
s 
th
at
 i
nj
ec
tio
n 
dr
ug
 u
se
 h
as
 c
on
tr
ib
ut
ed
 t
o 
th
e 
m
aj
or
ity
 o
f 
ne
w
 
H
C
V
 in
fe
ct
io
ns
 in
 I
ra
n[
4,
23
2]
.
D
is
tr
ib
u
ti
on
 o
f 
H
C
V
 g
en
ot
yp
es
 i
s 
va
ri
ab
le
 i
n
 d
iff
er
en
t 
g
ro
u
p
s 
an
d
 g
eo
g
ra
p
h
ic
 r
eg
io
n
s 
of
 I
ra
n
. 
Th
is
 g
en
ot
yp
ic
 v
ar
ia
b
ili
ty
 r
ef
le
ct
s 
d
iff
er
en
ce
s 
in
 t
h
e 
ro
u
te
s 
of
 
tr
an
sm
is
si
on
, 
po
pu
la
tio
n 
an
d 
so
ci
oe
co
no
m
ic
 f
ac
to
rs
, 
an
d 
th
e 
pr
es
en
ce
 o
f 
ri
sk
 f
ac
to
rs
 i
n 
th
e 
so
ci
et
y.
 T
hu
s,
 s
om
e 
ge
no
ty
pe
s 
ar
e 
m
or
e 
fr
eq
ue
nt
 i
n 
ce
rt
ai
n 
re
gi
on
s 
or
 
gr
ou
ps
 o
f 
pa
tie
nt
s[
4,
23
2]
. 
S
tu
di
es
 o
n 
th
e 
m
ol
ec
ul
ar
 e
pi
de
m
io
lo
gy
 o
f 
H
C
V
 i
n 
Ir
an
 a
re
 n
ee
de
d 
to
 r
ev
ea
l 
th
e 
cu
rr
en
t 
ge
no
ty
pi
c 
pa
tt
er
n 
of
 H
C
V
 i
nf
ec
tio
n 
in
 t
he
 c
ou
nt
ry
[2
28
] , 
w
hi
ch
 c
an
 p
re
di
ct
 t
he
 d
os
e,
 d
ur
at
io
n,
 a
nd
 t
yp
e 
of
 t
re
at
m
en
t 
as
 w
el
l a
s 
cl
in
ic
al
 o
ut
co
m
e 
of
 t
he
 in
fe
ct
io
n[
2,
22
8-
23
1]
.
O
C
C
U
LT
 H
C
V
 IN
FE
C
T
IO
N
 IN
 IR
A
N
O
cc
ul
t 
H
C
V
 in
fe
ct
io
n 
is
 d
es
cr
ib
ed
 b
y 
th
e 
ab
se
nc
e 
of
 d
et
ec
ta
bl
e 
H
C
V
-R
N
A
 a
nd
 a
nt
i-
H
C
V
 a
nt
ib
od
ie
s 
in
 s
er
um
 o
r 
pl
as
m
a 
w
ith
 e
le
va
te
d 
liv
er
 e
nz
ym
es
 o
r 
by
 t
he
 p
re
se
nc
e 
of
 
an
ti-
H
C
V
 a
nt
ib
od
ie
s 
bu
t 
un
de
te
ct
ab
le
 le
ve
ls
 o
f 
H
C
V
-R
N
A
 in
 s
er
um
 o
r 
pl
as
m
a 
w
ith
 n
or
m
al
 le
ve
ls
 o
f 
liv
er
 e
nz
ym
es
[2
52
-2
54
] . 
In
 b
ot
h 
ca
se
s,
 H
C
V
-R
N
A
 is
 d
et
ec
ta
bl
e 
in
 1
00
%
 
of
 l
iv
er
 b
io
ps
y,
 u
p 
to
 7
0%
 o
f 
pe
ri
ph
er
al
 b
lo
od
 m
on
on
uc
le
ar
 c
el
ls
 (
PB
M
C
s)
 s
pe
ci
m
en
s,
 a
nd
 i
n 
ne
ar
ly
 6
0%
 o
f 
ul
tr
ac
en
tr
ifu
ga
te
d 
se
ru
m
 s
am
pl
es
 o
f 
in
fe
ct
ed
 p
at
ie
nt
s[
25
5]
. 
O
cc
ul
t 
H
C
V
 c
an
 p
er
si
st
 a
nd
 r
ep
lic
at
e 
in
 h
ep
at
oc
yt
es
 a
nd
 ly
m
ph
oi
d 
ce
lls
 f
or
 a
 lo
ng
 t
im
e 
ev
en
 a
ft
er
 a
n 
ap
pa
re
nt
ly
 s
po
nt
an
eo
us
 e
ra
di
ca
tio
n 
or
 t
he
ra
py
-i
nd
uc
ed
 r
es
ol
ut
io
n 
of
 H
C
V
 i
nf
ec
tio
n[
25
6]
. 
In
 t
hi
s 
co
nd
iti
on
, 
lo
w
 c
op
y 
nu
m
be
rs
 o
f 
H
C
V
 R
N
A
 a
re
 p
re
se
nt
 i
n 
se
ru
m
 w
hi
le
 i
t 
ca
nn
ot
 b
e 
de
te
ct
ed
 b
y 
co
nv
en
tio
na
l 
R
T-
PC
R
 a
ss
ay
s 
bu
t 
re
m
ai
ns
 
po
te
nt
ia
lly
 in
fe
ct
io
us
[2
53
,2
54
] . 
D
is
tr
ib
ut
io
n 
of
 o
cc
ul
t 
H
C
V
 i
nf
ec
tio
n 
ha
s 
be
en
 r
ep
or
te
d 
al
l 
ar
ou
nd
 t
he
 w
or
ld
, 
an
d 
it 
se
em
s 
th
at
 a
ll 
ge
no
ty
pe
s 
ar
e 
in
vo
lv
ed
 i
n 
th
is
 i
nf
ec
tio
n[
25
3]
. 
A
 f
ew
 s
tu
di
es
 a
re
 
av
ai
la
bl
e 
re
ga
rd
in
g 
th
e 
pr
ev
al
en
ce
 o
f 
oc
cu
lt 
H
C
V
 i
n 
Ir
an
. 
B
ok
ha
ra
ei
-S
al
im
 e
t 
al
[2
51
]  
fo
un
d 
oc
cu
lt 
H
C
V
 i
n 
10
%
 (
7/
69
) 
of
 p
at
ie
nt
s 
w
ith
 c
ry
pt
og
en
ic
 l
iv
er
 d
is
ea
se
 i
n 
Ir
an
, 
w
hi
le
 4
3%
, 
29
%
, 
an
d 
29
%
 o
f 
th
es
e 
pa
tie
nt
s 
ha
d 
ge
no
ty
pe
s 
1b
, 
1a
 a
nd
 3
a,
 r
es
pe
ct
iv
el
y.
 K
ey
va
ni
 e
t 
al
[2
57
]  d
es
cr
ib
ed
 8
.9
%
 o
cc
ul
t 
H
C
V
 in
fe
ct
io
n 
w
ith
 g
en
ot
yp
es
 3
a 
(5
0%
) 
an
d 
1b
 (
50
%
) 
in
 p
at
ie
nt
s 
w
ith
 c
ry
pt
og
en
ic
 c
ir
rh
os
is
 i
n 
Ir
an
. 
Fa
ra
ha
ni
 e
t 
al
[2
58
]  
fo
un
d 
1.
9%
 o
cc
ul
t 
H
C
V
 i
nf
ec
tio
n 
w
ith
 g
en
ot
yp
e 
1a
 i
n 
pa
tie
nt
s 
w
ith
 l
ym
ph
op
ro
lif
er
at
iv
e 
di
so
rd
er
s 
in
 I
ra
n.
 M
ak
va
nd
i 
et
 a
l[2
59
]  
re
po
rt
ed
 3
2%
 o
cc
ul
t 
H
C
V
 i
nf
ec
tio
n 
in
 p
at
ie
nt
s 
w
ith
 a
bn
or
m
al
 l
ev
el
s 
of
 a
la
ni
ne
 a
m
in
ot
ra
ns
fe
ra
se
 i
n 
A
hv
az
 c
ity
. 
R
ez
ae
e 
Z
av
ar
eh
 e
t 
al
[2
60
]  
re
po
rt
ed
 t
he
 a
bs
en
ce
 o
f 
H
C
V
-R
N
A
 i
n 
PB
M
C
 s
am
pl
es
 o
f 
53
 p
at
ie
nt
s 
w
ith
 a
ut
oi
m
m
un
e 
he
pa
tit
is
 i
n 
Ir
an
. 
R
am
ez
an
i 
et
 a
l[2
61
] , 
re
po
rt
ed
 t
he
 a
bs
en
ce
 o
f 
oc
cu
lt 
H
C
V
 
10801 October 14, 2015|Volume 21|Issue 38|WJG|www.wjgnet.com
H
ae
m
od
ia
ly
si
s
Ea
st
 
A
ze
rb
ai
ja
n
N
or
th
-W
es
t
20
06
   
 5
5
   
  1
a:
 4
2 
(7
6.
4)
  3
a:
 3
 (5
.5
)
1 
(1
.8
)
  4
 (1
0.
9)
T
yp
e-
sp
ec
iﬁ
c 
p
ri
m
er
so
m
i
[2
48
]
 1
b:
 3
 (5
.5
)
H
ae
m
od
ia
ly
si
s
G
ila
n
N
or
th
20
08
   
 3
2
   
  1
a:
 1
9 
(5
9.
4)
  3
a:
 1
3 
(4
0.
6)
G
en
ot
yp
e-
sp
ec
iﬁ
c 
pr
im
er
s
Jo
uk
ar
[1
01
]
H
ae
m
od
ia
ly
si
s
Te
hr
an
N
or
th
-C
en
te
r
20
04
   
 6
6
   
  1
a:
 1
9 
(2
8.
8)
  3
a:
 2
0 
(3
0.
3)
4:
11
(1
6.
7)
2 
(3
.0
)
RF
LP
H
os
se
in
i-
M
og
ha
dd
am
[2
49
]
   
  1
b:
 1
2 
(1
8.
2)
  3
b:
 2
 (3
.0
)
H
IV
/H
C
V
 c
o-
in
fe
ct
io
n
Sh
ir
az
So
ut
h
20
04
-2
00
5
   
 5
0
  1
a:
 2
0 
(4
0)
  3
a:
 1
7 
(3
4.
0)
RF
LP
D
av
ar
pa
na
h
[2
50
]
  1
b:
 1
3 
(2
6)
O
cc
ul
t H
C
V
 in
fe
ct
ed
 
pa
tie
nt
s
Te
hr
an
N
or
th
-C
en
te
r
20
07
-2
01
0
   
   
7
1a
: 2
 (2
9)
   
 3
a:
 2
 (2
9.
0)
RF
LP
Bo
kh
ar
ae
i-S
al
im
[2
51
]
1b
: 3
 (4
3)
N
D
: N
ot
 d
eﬁ
n
ed
.
Taherkhani R et al . HCV in Iran
infection in 30 hemodialysis patients in Tehran.
Occult HCV infection has also been found in appa-
rently healthy populations[253,255]. The possible presence 
of occult HCV infection in the general population or 
blood donors poses a real concern about undetectable 
transmission of HCV[255,262]. In a recent study in Italy, 
the prevalence of occult HCV infection was higher than 
the frequency of anti-HCV seropositivity in the general 
population[262]. Therefore, the prevalence of HCV 
infection may be underestimated in the society[253,255], 
and the risk of HCV transmission through blood 
donation may be higher than predicted. Although 
screening of blood reduces the risk of HCV transmission 
by blood transfusion, transmission of occult HCV cannot 
be prevented in this way[253,255]. 
Currently, the prevalence of occult HCV infection 
in the general population of Iran and even blood 
donors is unknown. Therefore, further studies on the 
prevalence and significance of occult HCV in different 
cities are needed to identify the real burden of this 
infection in the country and subsequently in healthy 
subjects, especially among blood donors, to prevent 
the most of unknown transmission of HCV.
CONCLUSION
HCV infects large proportion of the high-risk popu-
lations in almost all regions of Iran and has a role 
in occurrence of different immunological disorders 
and even malignancies. The distribution patterns of 
HCV infection are related to different status of public 
health and the presence of risk factors in the society. 
Available estimates emphasize that injecting drug use 
is the most important risk factor for HCV infection in 
Iran and due to the growth in the number of injecting 
drug users, the prevalence of HCV infection is growing 
in the country. In addition, it seems that injection drug 
use has contributed to the occurrence of the majority 
of new HCV infections in Iran. Even the recent changes 
in the distribution pattern of HCV genotypes in Iranian 
patients confirm this issue. In fact, the predominance 
of risk factors for transmission of HCV has changed 
over time, from blood transfusion to intravenous drug 
use. The possible presence of occult HCV infection 
among the apparently healthy general population 
or blood donors proposes a real concern about 
undetectable transmission of HCV. Therefore, it seems 
that the prevalence of HCV infection will increase in 
near future not only among high-risk groups but even 
in the general population and blood donors of Iran. 
However, by breaking the cycle of infection among 
drug users, the rate of HCV infection will decrease. 
To approach this goal, efforts to screen, prevent, and 
treat HCV infection as well as reduce the high-risk 
behaviors are required. 
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Table 9  Global distribution of hepatitis C virus genotypes[4,229,230]
Region/country Predominant 
genotype/subtype
Uncommon 
genotype/subtype
Latin America
   Peru 1a 2
   Chile and Colombia 1b 2, 1a
   Brazil 1b, 1a, 3 4, 2
   Argentina 1b, 2, 1a 4
North America
   United States 1a, 1b, 2 4, 3
   Canada 1a, 3, 1b 4
Central Europe
   Albania 1b, 2, 4 1a, 3
   Bosnia and Herzegovina, 
   Czech Republic and Croatia
1b, 3 4, 2, 1a
   Hungary 1b, 1a 2, 4
   Romania 1b 3, 4
Western Europe
   Switzerland, Belgium, 
   Germany, Spain and France
1b, 3, 1a 5, 2, 4
   Italy 1b, 2 5, 3, 4
   United Kingdom and 
   Denmark
3, 1a 2
Eastern Europe
   Russia, Latvia, Lithuania and 
   Estonia
1b, 3 1a, 2
Central Africa 4 2
South Africa 5 2
West Africa
   Guinea-Bissau, Ghana and 
   Burkina Faso
2 1
East Africa
   Ethiopia 4, 2 1
North Africa
   Tunisia, Morocco, Algeria 1b, 2 4
Middle East 
   Saudi Arabia, Bahrain, 
   Yemen, Kuwait, Qatar, 
   Iraq and Egypt
4 1, 3, 2
   Jordan 1a, 1b, 4 -
   Iran 1a, 3a, 1b 4, 2
   Turkey 1b 4, 2, 3, 1a
Asia Paciﬁc
   Japan and Korea 1b, 2 1a
Asia, Central
   Uzbekistan, Tajikistan, 
   Turkmenistan and Georgia
1b 1a
East Asia 
   China, Taiwan 1b, 2 1a, 3, 6
   South East Asia
   Laos 6 1
   Philippines 1a, 2 6, 4
   Thailand 3 2
   Myanmar 6 2
   Malaysia 3 4
South Asia 
   Pakistan and India 3 1b, 2, 4
Australasia
   Australia and New Zealand 3, 1a, 1b 4, 2
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